Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metastasis Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PTP4A3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PTP4A3 (PRL-3) Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Optimized for enzymatic and binding assays. |
View PTP4A3 Products |
| Gene Delivery | PTP4A3 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and surface-expression validation. |
View PTP4A3 Products |
| Benchmark Ab | Anti-PTP4A3 Recombinant Antibody Sequence derived from clinical benchmark (PRL3-zumab). Recombinant positive control. |
View PTP4A3 Products |
| Validator | PTP4A3 siRNA Set For target knockdown verification and specificity profiling. |
View PTP4A3 Products |
| Related Target A | PTP4A1 (PRL-1) High-homology family member (>75% sequence identity) required for selectivity counter-screening. |
View PTP4A1 Products |
| Related Target B | PTP4A2 (PRL-2) High-homology family member (>85% sequence identity) required for selectivity counter-screening. |
View PTP4A2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Selectivity (PRL-1/2/3) | Highly purified recombinant PTP4A1, PTP4A2, and PTP4A3 proteins verified by SDS-PAGE and Mass Spectrometry. |
| Atypical Surface Target Validation | Lentivirus-premade particles for stable cell line construction to mimic native membrane-associated conformation. |
| Lack of Controls | Recombinant clinical benchmark antibody (PRL3-zumab biosimilar) available as a positive control. |
| False Positives | Validated siRNA pool included for target-specific knockdown verification. |
Live PTP4A3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PTP4A3 (PRL-3) therapeutics is intensifying, with major players shifting focus from traditional intracellular small-molecule inhibitors to unconventional extracellular-targeting monoclonal antibodies. As first-generation therapies reach the clinic, the next wave of R&D is targeting tumor-specific externalized PRL-3, bypassing the historical "undruggable" nature of intracellular phosphatases.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Intra-Link Technologies, A*STAR | Gastric, Colorectal, and Breast Cancers | Atypical surface binding & internalization assays (Need Lentivirus for stable cell lines) |
| Small Molecule Inhibitors | Academic Institutions, Biotech Startups | Hematological Malignancies, Solid Tumors | Enzymatic phosphatase assays & selectivity panels (Need PTP4A1/2/3 recombinant proteins) |
| CAR-T / TCR-T | Early Stage Biotechs | PRL-3 Overexpressing Metastatic Cancers | Target density and specificity validation (Need sequence-verified ORF expression) |